Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 1/20 | 0.43 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.43 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.36 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.36 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.33 |
| ▸ | DRD3 | P35462 | 2/20 | 0.33 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.33 |
| ▸ | GID4 | Q8IVV7 | 1/20 | 0.31 |
| ▸ | DRD2 | P14416 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7577546 | 0.79 | TAAR1 (0.38) | TAAR1DRD2 | |
| SCHEMBL3138571 | 0.78 | — | — | |
| SCHEMBL3130831 | 0.75 | CYP19A1 (0.38) | CYP19A1TBXAS1GID4 | |
| SCHEMBL3128756 | 0.74 | PNMT (0.32) | — | |
| SCHEMBL3137748 | 0.74 | RXRA (0.30) | — | |
| SCHEMBL868057 | 0.71 | CHRNB2 (0.32) | — | |
| SCHEMBL3135314 | 0.71 | — | — | |
| SCHEMBL3135318 | 0.71 | — | — | |
| SCHEMBL3135307 | 0.71 | — | — | |
| SCHEMBL13686434 | 0.70 | ADRA2A (0.42) | ADRA2AADRA2BADRA2CLMNACYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020049223-A1 | Quinoline and naphthyridine carboxylic acid antibacterials | ABBOTT LABORATORIES | 2002-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020049223-A1 | Quinoline and naphthyridine carboxylic acid antibacterials | NQO2, NQO1, NDUFA7 | ADRA2A 2581/4885ADRA2B 2506/4885ADRA2C 2432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.